Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Horowitz

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Heart (British Cardiac Society)|July 14, 2012
Slowly resolving global myocardial inflammation/oedema in Tako-Tsubo cardiomyopathy: evidence from T2-weighted cardiac MRIChristopher Neil, Thanh Ha Nguyen, Angela Kucia, et al.
American Heart Journal|May 15, 2022
Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state modelJulia Aulin, Ziad Hijazi, Johan Lindbäck, et al.
American Heart Journal|September 1, 2014
Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) TrialShinya Goto, Jun Zhu, Lisheng Liu, et al.
European Heart Journal|March 19, 2014
Intravenous sodium nitrite in acute ST-elevation myocardial infarction: a randomized controlled trial (NIAMI)Nishat Siddiqi, Christopher Neil, Margaret Bruce, et al.
Journal of the American College of Cardiology|April 9, 2013
N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation)Ziad Hijazi, Lars Wallentin, Agneta Siegbahn, et al.
Journal of Thrombosis and Haemostasis : JTH|June 9, 2020
Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trialsJulia Aulin, Ziad Hijazi, Agneta Siegbahn, et al.
Circulation|November 15, 2013
High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trialZiad Hijazi, Agneta Siegbahn, Ulrika Andersson, et al.
Journal of Thrombosis and Thrombolysis|February 22, 2019
Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE TrialJeffrey B Washam, Stefan H Hohnloser, Renato D Lopes, et al.
American Heart Journal|March 10, 2010
Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationaleRenato D Lopes, John H Alexander, Sana M Al-Khatib, et al.
Clinical Chemistry|December 3, 2014
Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudyZiad Hijazi, Agneta Siegbahn, Ulrika Andersson, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Heart (British Cardiac Society)|July 14, 2012
Slowly resolving global myocardial inflammation/oedema in Tako-Tsubo cardiomyopathy: evidence from T2-weighted cardiac MRIChristopher Neil, Thanh Ha Nguyen, Angela Kucia, et al.
American Heart Journal|May 15, 2022
Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state modelJulia Aulin, Ziad Hijazi, Johan Lindbäck, et al.
American Heart Journal|September 1, 2014
Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) TrialShinya Goto, Jun Zhu, Lisheng Liu, et al.
European Heart Journal|March 19, 2014
Intravenous sodium nitrite in acute ST-elevation myocardial infarction: a randomized controlled trial (NIAMI)Nishat Siddiqi, Christopher Neil, Margaret Bruce, et al.
Journal of the American College of Cardiology|April 9, 2013
N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation)Ziad Hijazi, Lars Wallentin, Agneta Siegbahn, et al.
Journal of Thrombosis and Haemostasis : JTH|June 9, 2020
Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trialsJulia Aulin, Ziad Hijazi, Agneta Siegbahn, et al.
Circulation|November 15, 2013
High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trialZiad Hijazi, Agneta Siegbahn, Ulrika Andersson, et al.
Journal of Thrombosis and Thrombolysis|February 22, 2019
Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE TrialJeffrey B Washam, Stefan H Hohnloser, Renato D Lopes, et al.
American Heart Journal|March 10, 2010
Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationaleRenato D Lopes, John H Alexander, Sana M Al-Khatib, et al.
Clinical Chemistry|December 3, 2014
Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudyZiad Hijazi, Agneta Siegbahn, Ulrika Andersson, et al.
Pageof 4